Recipharm AB (RECI B):企業の財務・戦略的SWOT分析

◆英語タイトル:Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1634
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Recipharm AB (RECI B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The company’s manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology services supports customers from initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel and the US. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

Mar 06,2020 Recipharm completes delisting of Consort Medical
Mar 06,2020 Recipharm notes an increased demand for Chloroquine Phosphate

Feb 20,2020 Recipharm publishes report for the fourth quarter and full year 2019
Feb 07,2020 Recipharm announces that Consort Medical applies for delisting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Recipharm AB – Key Facts
Recipharm AB – Key Employees
Recipharm AB – Key Employee Biographies
Recipharm AB – Major Products and Services
Recipharm AB – History
Recipharm AB – Company Statement
Recipharm AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Recipharm AB – Business Description
Business Segment: D&T
Overview
Performance
Business Segment: MFG-SI
Overview
Performance
Business Segment: MFG-SO
Overview
Performance
Geographical Segment: France
Performance
Geographical Segment: Germany
Performance
Geographical Segment: India
Performance
Geographical Segment: Italy
Performance
Geographical Segment: Other
Performance
Geographical Segment: Portugal
Performance
Geographical Segment: Spain
Performance
Geographical Segment: Sweden
Performance
Geographical Segment: UK
Performance
Recipharm AB – Corporate Strategy
Recipharm AB – SWOT Analysis
SWOT Analysis – Overview
Recipharm AB – Strengths
Recipharm AB – Weaknesses
Recipharm AB – Opportunities
Recipharm AB – Threats
Recipharm AB – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recipharm AB, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 06, 2020: Recipharm completes delisting of Consort Medical
Mar 06, 2020: Recipharm notes an increased demand for Chloroquine Phosphate
Feb 20, 2020: Recipharm publishes report for the fourth quarter and full year 2019
Feb 07, 2020: Recipharm announces that Consort Medical applies for delisting
Feb 05, 2020: Consort Medical becomes part of the Recipharm Group
Dec 09, 2019: Recipharm invests in its US inhalation development service
Nov 18, 2019: Recipharm to communicate new financial targets on Capital Markets Day
Nov 14, 2019: Recipharm joins the AMR Industry Alliance
Nov 07, 2019: Recipharm publishes its interim report January – September 2019
Nov 06, 2019: Recipharm expands Indian injectable dosage form capabilities through new partnership
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Recipharm AB, Key Facts
Recipharm AB, Key Employees
Recipharm AB, Key Employee Biographies
Recipharm AB, Major Products and Services
Recipharm AB, History
Recipharm AB, Other Locations
Recipharm AB, Subsidiaries
Recipharm AB, Key Competitors
Recipharm AB, Ratios based on current share price
Recipharm AB, Annual Ratios
Recipharm AB, Annual Ratios (Cont...1)
Recipharm AB, Annual Ratios (Cont...2)
Recipharm AB, Interim Ratios
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Recipharm AB, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Recipharm AB, Performance Chart (2015 - 2019)
Recipharm AB, Ratio Charts
Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Recipharm AB (RECI B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • amcure GmbH-製薬・医療分野:企業M&A・提携分析
    Summary amcure GmbH (Amcure) is biopharmaceutical company which discovers and develops therapeutics for the treatment of cancer. It develops peptide-based compounds for the treatment of metastatic forms of cancer. The company’s lead candidate AMC303, is in Phase I clinical trial and used for the tre …
  • Nishat Mills Ltd:企業の戦略・SWOT・財務分析
    Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report Summary Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • The US Oncology Network:企業の戦略的SWOT分析
    The US Oncology Network - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Adaptimmune Therapeutics Plc (ADAP):製薬・医療:M&Aディール及び事業提携情報
    Summary Adaptimmune Therapeutics Plc (Adaptimmune), formerly Adaptimmune Therapeutics Limited, is a clinical stage biopharmaceutical company that develops innovative T-cell therapy products for the treatment of cancer. It harnesses the proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) …
  • Jupiter Telecommunications Co Ltd:企業の戦略的SWOT分析
    Jupiter Telecommunications Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Alpha Petroleum Resources Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Alpha Petroleum Resources Ltd (Alpha Petroleum), formerly ATP Oil & Gas (UK) Ltd, a subsidiary of Alpha Petroleum (UK) Holdings Ltd, is an upstream oil and gas company that offers operation, development and production activities in the UK sector of the North Sea. The company operates product …
  • BKW AG:企業の戦略・SWOT・財務分析
    BKW AG - Strategy, SWOT and Corporate Finance Report Summary BKW AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Solvay S.A:企業の戦略・SWOT・財務分析
    Solvay S.A - Strategy, SWOT and Corporate Finance Report Summary Solvay S.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Oil India Ltd (OIL):企業の財務・戦略的SWOT分析
    Oil India Ltd (OIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Mentor Graphics Corporation:企業の戦略・SWOT・財務分析
    Mentor Graphics Corporation - Strategy, SWOT and Corporate Finance Report Summary Mentor Graphics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Daicel Corp (4202):企業の財務・戦略的SWOT分析
    Daicel Corp (4202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Iowa Health System:企業の戦略的SWOT分析
    Iowa Health System - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Tokyo Seimitsu Co., Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Seimitsu Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Seimitsu Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Mangalore Refinery and Petrochemicals Ltd (MRPL):企業の財務・戦略的SWOT分析
    Mangalore Refinery and Petrochemicals Ltd (MRPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Shangri-La Asia Ltd:企業の戦略・SWOT・財務情報
    Shangri-La Asia Ltd - Strategy, SWOT and Corporate Finance Report Summary Shangri-La Asia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Romark Laboratories LC:製薬・医療:M&Aディール及び事業提携情報
    Summary Romark Laboratories LC (Romark Laboratories) is a pharmaceutical company that discovers, develops and commercializes small molecules for the treatment of infectious diseases and cancers. The company develops Nitazoxanide, an oral suspension and tablets used for the treatment of intestinal pa …
  • Chicago Bridge & Iron Company NV (CBI):石油・ガス:M&Aディール及び事業提携情報
    Summary Chicago Bridge & Iron Company NV (CB&I) is a provider of technology and infrastructure solutions. Its services include conceptual design, technology, engineering, procurement, modularization, construction, fabrication, commissioning, maintenance, program management and environmental services …
  • Daigas Group:企業の戦略・SWOT・財務分析
    Daigas Group - Strategy, SWOT and Corporate Finance Report Summary Daigas Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Tryton Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Tryton Medical Inc (Tryton Medical) is a medical device company that develops novel stent systems for the treatment of bifurcation lesions. The company offers tryton side branch coronary artery stent which is designed to treat, protect and secure coronary bifurcations. Its tryton side branch …
  • OJSC Surgutneftegas:企業の戦略・SWOT・財務分析
    OJSC Surgutneftegas - Strategy, SWOT and Corporate Finance Report Summary OJSC Surgutneftegas - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆